

**NATIONAL HEART, LUNG, AND BLOOD INSTITUTE
NATIONAL ASTHMA EDUCATION AND PREVENTION PROGRAM
ASTHMA AND PREGNANCY WORKING GROUP**

**QUICK REFERENCE
NAEPP EXPERT PANEL REPORT
Managing Asthma During Pregnancy:
Recommendations for Pharmacologic Treatment—2004 Update**

ACKNOWLEDGMENTS

NATIONAL ASTHMA EDUCATION AND PREVENTION PROGRAM ASTHMA AND PREGNANCY WORKING GROUP

William W. Busse, MD, <i>Chair</i> University of Wisconsin Medical School Madison, WI	Harold S. Nelson, MD National Jewish Medical and Research Center Denver, CO	Anthony R. Scialli, MD Georgetown University Hospital Washington, DC
Michelle Cloutier, MD Connecticut Children's Medical Center Hartford, CT	Michael Reed, PharmD Rainbow Babies and Children's Hospital Cleveland, OH	Stuart Stoloff, MD University of Nevada School of Medicine Reno, NV
Mitchell Dombrowski, MD St. John Hospital Detroit, MI	Michael Schatz, MD, MS Kaiser-Permanente Medical Center San Diego, CA	Stanley Szeffler, MD National Jewish Medical and Research Center Denver, CO

NATIONAL HEART, LUNG, AND BLOOD INSTITUTE STAFF

Robinson Fulwood, PhD, MSPH Senior Manager Public Health Program Development Office of Prevention, Education, and Control	James P. Kiley, PhD Director Division of Lung Diseases Gregory J. Morosco, PhD, MPH Associate Director Office of Prevention, Education, and Control	Diana K. Schmidt, MPH Coordinator National Asthma Education and Prevention Program Virginia S. Taggart, MPH Health Scientist Administrator Division of Lung Diseases
---	---	--

AMERICAN INSTITUTES FOR RESEARCH, HEALTH PROGRAM, SUPPORT STAFF

Teresa Wilson, MPH, RN Senior Program Manager	Susan Bratten Senior Editor	Patricia Louthian Desktop Publishing Specialist
--	--------------------------------	--

**NATIONAL ASTHMA EDUCATION AND PREVENTION PROGRAM SCIENCE BASE COMMITTEE ON THE
MANAGEMENT OF ASTHMA**

William W. Busse, MD, <i>Chair</i> University of Wisconsin Medical School Madison, WI	H. William Kelly, PharmD University of New Mexico Health Sciences Center Albuquerque, NM	Harold S. Nelson, MD National Jewish Medical and Research Center Denver, CO
Homer A. Boushey, MD University of California at San Francisco San Francisco, CA	Robert F. Lemanske, MD University of Wisconsin Hospital and Clinics Madison, WI	Gail Shapiro, MD University of Washington Seattle, WA
Sonia Buist, MD Oregon Health Sciences University Portland, OR	Fernando D. Martinez, MD University of Arizona Medical Center Tucson, AZ	Stuart Stoloff, MD University of Nevada School of Medicine Reno, NV
Noreen M. Clark, PhD University of Michigan School of Public Health Ann Arbor, MI		Stanley Szeffler, MD National Jewish Medical and Research Center Denver, CO

NATIONAL ASTHMA EDUCATION AND PREVENTION PROGRAM COORDINATING COMMITTEE

Barbara Alving, MD, <i>Chair</i> National Heart, Lung, and Blood Institute	Paul V. Williams, MD American Medical Association	Lara Akinbami, MD National Center for Health Statistics Centers for Disease Control and Prevention
Denise Dougherty, PhD Agency for Health Care Policy and Research	Karen Huss, DNSc, FAAN, FAAAAI, NINR American Nurses Association	Ruth I. Quarkey, MA, RRT National Heart, Lung, and Blood Institute Ad Hoc Committee on Minority Populations
Christy Olson Allergy and Asthma Network/Mothers of Asthmatics, Inc	Dennis M. Williams, PharmD American Pharmacists Association	Gregory R. Wagner, MD National Institute for Occupational Safety and Health Centers for Disease Control and Prevention
Gail Shapiro, MD American Academy of Allergy, Asthma, and Immunology	Pamela J. Luna, DrPH, MEd American Public Health Association	Peter Gergen, MD, MPH National Institute of Allergy and Infectious Diseases
Barbara P. Yawn, MD, MSc American Academy of Family Physicians	Lani S. M. Wheeler, MD, FAAP, FASHA American School Health Association	J. Patrick Mastin, PhD National Institute of Environmental Health Sciences
Gary S. Rachelefsky, MD American Academy of Pediatrics	Leslie Hendeles, PharmD American Society of Health-System Pharmacists	Michael Lenoir, MD National Medical Association
Gabriel R. Ortiz, MPAS, PA-C American Academy of Physician Assistants	Stephen C. Lazarus, MD American Thoracic Society	Carlos A. Camargo, MD, DrPH Society for Academic Emergency Medicine
Thomas J. Kallstrom, RRT American Association for Respiratory Care	Bill McLin Asthma and Allergy Foundation of America	Estelle Bogdonoff, MPH, CHES Judith Taylor-Fishwick, MSc, AE-C Society for Public Health Education
Pam Carter, RN, COHN-S American Association of Occupational Health Nurses	Sarah Lyon-Callo, MA, MS Council on State and Territorial Epidemiologists	Dana Carr Doris Sligh US Department of Education
William Storms, MD American College of Allergy, Asthma, and Immunology	Linda Wolfe, RN, MEd National Association of School Nurses	David E. Jacobs, PhD US Department of Housing and Urban Development
John P. Mitchell, MD, FACP American College of Chest Physicians	Susan B. Clark, RN, MN National Black Nurses Association, Inc	Bob Axelrad US Environmental Protection Agency
Richard M. Nowak, MD, MBA, FACEP American College of Emergency Physicians	Sarah Merkle, MPH National Center for Chronic Disease Prevention Centers for Disease Control and Prevention	Robert J. Meyer, MD US Food and Drug Administration
Scott Wolf, DO, MPH, FACP American College of Physicians	Leslie P. Boss, PhD, MPH National Center for Environmental Health Centers for Disease Control and Prevention	
Noreen M. Clark, PhD American Lung Association		

The working group acknowledges the following consultants for their review of an early draft of the report:

Yoram Sorokin, MD, FACOG Department of Obstetrics and Gynecology, Hutzel Hospital Detroit, MI	Brian M. Mercer, MD, FCRSC, FACOG MetroHealth Medical Center Cleveland, OH	Alan M. Peaceman, MD Northwestern University Feinberg School of Medicine Chicago, IL
--	--	---

NAEPP Expert Panel Report

Managing Asthma During Pregnancy: Recommendations for Pharmacologic Treatment—2004 Update

Key words: Asthma, beta₂-agonists, cromolyn, infant, inhaled and oral corticosteroids, lactation, leukotriene modifiers, NAEPP, pregnancy, pharmacologic treatment, theophylline

Maintaining adequate control of asthma during pregnancy is important for the health and well-being of both the mother and her baby. Asthma has been reported to affect 3.7 to 8.4 percent of pregnant women,¹ making it potentially the most common serious medical problem to complicate pregnancy. The largest and most recent studies suggest that maternal asthma increases the risk of perinatal mortality, preeclampsia, preterm birth, and low birth weight infants. More severe asthma is associated with increased risks,^{2,3} while better-controlled asthma is associated with decreased risks.⁴

In 1993, the National Asthma Education and Prevention Program (NAEPP) published the *Report of the Working Group on Asthma and Pregnancy* (Asthma and Pregnancy

Abbreviations used

DPI:	Dry powder inhaler
EPR:	Expert Panel Report
FDA:	Food and Drug Administration
FEV ₁ :	Forced expiratory volume in 1 second
MDI:	Metered-dose inhaler
NAEPP:	National Asthma Education and Prevention Program
PEF:	Peak expiratory flow
PCO ₂ :	Carbon dioxide partial pressure

Report 1993),⁵ which presented recommendations for the management of asthma during pregnancy. Since then, there have been revisions to the general asthma treatment guidelines, *Guidelines for the Diagnosis and Management of Asthma—Expert Panel Report 2* (EPR-2 1997),⁶ and *Expert Panel Report: Guidelines for the Diagnosis and Management of Asthma—Update on Selected Topics 2002* (EPR—Update 2002)⁷; release of new asthma medications; and publication of new gestational safety data.

Managing Asthma During Pregnancy: Recommendations for Pharmacologic Treatment—Update 2004 (EPR—Update 2004)⁸ reflects the NAEPP's commitment to keep recommendations for clinical practice up to date and based on systematic reviews of the evidence. EPR—Update 2004 was developed through the collective expertise of an expert panel on asthma and pregnancy (Working Group), the NAEPP Science Base Committee, and NAEPP Coordinating Committee members. The recommendations made in EPR—Update 2004 are intended to assist clinical decision-making; the clinician and patient still need to develop individual treatment plans that are tailored to the specific needs and circumstances of the patient.

The scope of the current systematic review is pharmacologic treatment of asthma in women during their pregnancy; however, highlights from EPR-2 1997 and EPR—Update 2002 relative to other aspects of asthma care are also presented because they should enhance the overall success and safety of managing asthma in pregnancy.

SYSTEMATIC REVIEW OF THE EVIDENCE

A systematic review of the evidence on the safety of asthma medications during pregnancy was conducted by drug class. Of 226 articles retrieved in the search of

Disclosure of potential conflict of interest: W.W. Busse has consultant arrangements with Bristol-Myers Squibb, Dynavax, Hoffman LaRoche, Fujisawa, and Wyeth; receives grants/research support from GlaxoSmithKline, Fujisawa, Aventis, Hoffman LaRoche, Pfizer, and Wyeth; is on the Speakers' Bureau of GlaxoSmithKline, Aventis, and Merck; and is on the Advisory Board of GlaxoSmithKline, Aventis, Schering, Pfizer, and AstraZeneca. M. Cloutier received an Easy Breathing Educational grant and receives grants/research support from GlaxoSmithKline. M. Dombrowski—none disclosed. H.S. Nelson has consultant arrangements with Rigel Pharmaceuticals, Dey Laboratories, GlaxoSmithKline, Altana, AstraZeneca, Aventis, Integrated Therapeutics Group, UCB, Genentech, Protein Design Laboratories, Dynavax Technologies, and Wyeth; receives grants/research support from Dey Laboratories, IVAX, Eli Lilly, Altana, Epigenesis, and AstraZeneca; and is on the Speakers' Bureau of GlaxoSmithKline and AstraZeneca. M. Reed has consultant arrangements with Abbott Laboratories, Bristol-Myers Squibb, Enzon, GlaxoSmithKline, Pfizer, and Somerset; receives grants/research support from Abbott Laboratories, AstraZeneca, Aventis, Bristol-Myers Squibb, Eli Lilly, Forrest Laboratories, GlaxoSmithKline, Janssen, Johnson & Johnson, Merck, Novartis, Organon, Pfizer, Roche, Schering, Somerset, and Wyeth-Ayerst; and is on the Speakers' Bureau of Abbott Laboratories, Bristol-Myers Squibb, Enzon, GlaxoSmithKline, Pfizer, Roche, and Somerset. M. Schatz receives grants/research support from GlaxoSmithKline and Aventis and is on the Speakers' Bureau of Merck and AstraZeneca. A.R. Scialli—none disclosed. S. Stolfi has consultant arrangements with GlaxoSmithKline, AstraZeneca, Schering, Aventis, Genentech, Alcon, and Pfizer and is on the Speakers' Bureau of GlaxoSmithKline, AstraZeneca, Schering, Aventis, Genentech, Alcon, and Pfizer. S. Szeffer has consultant arrangements with AstraZeneca, GlaxoSmithKline, Aventis, and Merck and receives grants/research support from Russ Pharmaceuticals and AstraZeneca.

J Allergy Clin Immunol 2005;115:34-46.

0091-6749

doi:10.1016/j.jaci.2004.10.023

literature published in peer-reviewed journals from January 1990 through May 2003, 42 met criteria for inclusion in the evidence review; 2 additional articles published after May 2003 were included, for a total of 44 articles. A summary of the findings from the evidence, arranged by medication category, follows.

Beta₂-Agonists

One experimental animal study⁹ and six human studies were included. The six human studies consisted of one case report¹⁰ and five clinical studies¹¹⁻¹⁵ that included a total of 6,667 pregnant women, of whom 1,929 had asthma and 1,599 had taken beta₂-agonists. The data were reassuring regarding the safety of beta₂-agonists during pregnancy. More data were available for albuterol. Two long-acting inhaled beta₂-agonists have become available since 1993—salmeterol and formoterol. Limited data are available on their use during pregnancy. The pharmacologic and toxicologic profiles of these two drugs are similar to the short-acting inhaled beta₂-agonists, with the exception of their prolonged retention in the lungs.

Theophylline

Seven experimental animal studies¹⁶⁻²² and eight human studies were included. The experimental animal studies confirm the association of high-dose theophylline and adverse pregnancy outcomes in animals. The eight human studies, consisting of two case reports^{23,24} and six clinical studies^{11,13,25-28} (of which two were randomized controlled trials), included a total of 57,163 pregnant women, of whom 3,616 had asthma and 660 had taken theophylline. Studies and clinical experience confirm the safety of theophylline at recommended doses (to serum concentration of 5–12 mcg/mL) during pregnancy. In a randomized controlled trial, there were no differences in asthma exacerbations or maternal or perinatal outcomes in the theophylline versus the beclomethasone dipropionate treatment groups. However, in the theophylline treatment group, there were higher levels of reported side effects and discontinuation of the medication and an increase in the proportion of women with forced expiratory volume in 1 second (FEV₁) at less than 80 percent of that predicted.²⁵

Anticholinergics

No data on anticholinergics were available for the current evidence review.

Inhaled corticosteroids

Three experimental animal studies²⁹⁻³¹ and 10 human studies were included. The human studies included eight studies of pregnant women. Of the eight studies, five were cohort studies,^{11,13,32-34} one was a controlled trial,³⁵ and two were randomized controlled trials.^{25,28} These eight studies included a total of 21,072 pregnant women, of whom 16,900 had asthma and 6,113 had taken inhaled corticosteroids. Also included were two studies of newborns from the Swedish Birth Registry—one compared the rate of abnormalities among 2,014 newborns whose

mothers had taken budesonide to the rate of abnormalities in the total newborn population, although the number in that population was not reported;³⁶ the other study compared 2,900 newborns whose mothers had taken budesonide to the total newborn population of 293,948;³⁷ there may be some overlap in the populations of these two studies. There are three major conclusions from the evidence review: (1) the risk of asthma exacerbations associated with pregnancy can be reduced and lung function (FEV₁) improved with the use of inhaled corticosteroid therapy;^{25,28,34} (2) no studies to date, including studies of large birth registries, have related inhaled corticosteroid use to any increases in congenital malformations or other adverse perinatal outcomes; and (3) the preponderance of data on inhaled corticosteroids during pregnancy is with budesonide (few or no studies are available on the other inhaled corticosteroid formulations during pregnancy).



Oral (systemic) corticosteroids

Nine experimental animal studies³⁸⁻⁴⁶ and eight human studies were included. The animal studies do not change the previous understanding (Asthma and Pregnancy Report 1993)⁵ of the steroid-mediated clefting or decreases in fetal growth in animals. The eight human studies in the current evidence review included one report of two meta-analyses:⁴⁷ one meta-analysis used six cohort studies that included 51,380 pregnant women, of whom 535 had taken oral corticosteroids; the other meta-analysis used four case-control studies,⁴⁸⁻⁵¹ each of which was also eligible to be included in the evidence review. These four case-control studies included 52,038 pregnant women, of whom 25 had taken oral corticosteroids. The remaining three human studies included one case-control study⁵² and two prospective cohort studies^{11,13} that included a total of 4,321 pregnant women, of whom 1,998 had asthma and 213 had taken oral corticosteroids. The findings from the current evidence review are conflicting. Oral corticosteroid use, especially during the first trimester of pregnancy, is associated with an increased risk for isolated cleft lip with or without cleft palate (the risk in the general population is 0.1 percent; the risk in women on oral corticosteroids is 0.3 percent).⁴⁷ However, very few pregnant women who had oral steroid-dependent asthma were included in the studies, and the length, timing, and dose of exposure to the drug were not well described. Oral corticosteroid use during pregnancy in patients who have asthma is associated with an increased incidence of pre-eclampsia and the delivery of both preterm and low birth weight infants.^{13,47,52} However, the available data make it difficult to separate the effects of the oral corticosteroids on these outcomes from the effects of severe or uncontrolled asthma, which has been associated with maternal and/or fetal mortality.

Cromolyn

No experimental animal studies and two human studies were included in the current review. The two human studies consisted of prospective cohort studies^{11,13} that included 4,110 pregnant women, of whom 1,917 had

Classify Severity: Clinical Features Before Treatment or Adequate Control			Medications Required To Maintain Long-Term Control
	Symptoms/Day Symptoms/Night	PEF or FEV ₁ PEF Variability	Daily Medications
Step 4 Severe Persistent	Continual Frequent	≤60% >30%	<ul style="list-style-type: none"> Preferred treatment: <ul style="list-style-type: none"> High-dose inhaled corticosteroid* AND Long-acting inhaled beta₂-agonist AND, if needed, Corticosteroid tablets or syrup long term (2 mg/kg per day, generally not to exceed 60 mg per day). (Make repeat attempts to reduce systemic corticosteroid and maintain control with high-dose inhaled corticosteroid.*) Alternative treatment: <ul style="list-style-type: none"> High-dose inhaled corticosteroid* AND Sustained release theophylline to serum concentration of 5–12 mcg/mL.
Step 3 Moderate Persistent	Daily >1 night/week	>60%–<80% >30%	<ul style="list-style-type: none"> Preferred treatment: <ul style="list-style-type: none"> EITHER Low-dose inhaled corticosteroid* and long-acting inhaled beta₂-agonist OR Medium-dose inhaled corticosteroid.* If needed (particularly in patients with recurring severe exacerbations): Medium-dose inhaled corticosteroid* and long-acting inhaled beta₂-agonist. Alternative treatment: <ul style="list-style-type: none"> Low-dose inhaled corticosteroid* and either theophylline or leukotriene receptor antagonist.† If needed: Medium-dose inhaled corticosteroid* and either theophylline or leukotriene receptor antagonist.†
Step 2 Mild Persistent	>2 days/week but <daily >2 nights/month	≥80% 20%–30%	<ul style="list-style-type: none"> Preferred treatment: <ul style="list-style-type: none"> Low-dose inhaled corticosteroid.* Alternative treatment (listed alphabetically): cromolyn, leukotriene receptor antagonist† OR sustained-release theophylline to serum concentration of 5–12 mcg/mL.
Step 1 Mild Intermittent	≤2 days/week ≤2 nights/month	≥80% <20%	<ul style="list-style-type: none"> No daily medication needed. Severe exacerbations may occur, separated by long periods of normal lung function and no symptoms. A course of systemic corticosteroid is recommended.
Quick Relief All Patients	<ul style="list-style-type: none"> Short-acting bronchodilator: 2–4 puffs short-acting inhaled beta₂-agonist‡ as needed for symptoms. Intensity of treatment will depend on severity of exacerbation; up to 3 treatments at 20-minute intervals or a single nebulizer treatment as needed. Course of systemic corticosteroid may be needed. Use of short-acting inhaled beta₂-agonist‡ >2 times a week in intermittent asthma (daily, or increasing use in persistent asthma) may indicate the need to initiate (increase) long-term-control therapy. 		

	Step down Review treatment every 1–6 months; a gradual stepwise reduction in treatment may be possible.
	Step up If control is not maintained, consider step up. First, review patient medication technique, adherence, and environmental control.
Goals of Therapy: Asthma Control	
<ul style="list-style-type: none"> Minimal or no chronic symptoms day or night Minimal or no exacerbations No limitations on activities; no school/work missed 	<ul style="list-style-type: none"> Maintain (near) normal pulmonary function Minimal use of short-acting inhaled beta₂-agonist‡ Minimal or no adverse effects from medications

*There are more data on using budesonide during pregnancy than on using other inhaled corticosteroids.

†There are minimal data on using leukotriene receptor antagonists in humans during pregnancy, although there are reassuring animal data submitted to FDA.

‡There are more data on using albuterol during pregnancy than on using other short-acting inhaled beta₂-agonists.

Notes:

- The stepwise approach is meant to assist, not replace, the clinical decisionmaking required to meet individual patient needs.
- Classify severity: assign patient to most severe step in which any feature occurs (PEF is percent of personal best; FEV₁ is percent predicted).
- Gain control as quickly as possible (consider a short course of systemic corticosteroid), then step down to the least medication necessary to maintain control.
- Minimize use of short-acting inhaled beta₂-agonist‡ (e.g., use of approximately one canister a month even if not using it every day indicates inadequate control of asthma and the need to initiate or intensify long-term-control therapy).
- Provide education on self-management and controlling environmental factors that make asthma worse (e.g., allergens, irritants).
- Refer to an asthma specialist if there are difficulties controlling asthma or if Step 4 care is required. Referral may be considered if Step 3 care is required.

FIG 1. Stepwise approach for managing asthma during pregnancy and lactation: treatment.

asthma and 318 had taken cromolyn. The safety of using cromolyn during pregnancy is supported by the current review of evidence.

Leukotriene modifiers

Leukotriene modifiers include two compounds available as oral tablets (the receptor antagonists montelu-

kast and zafirlukast) and 5-lipoxygenase pathway inhibitors (e.g., zileuton). No animal studies and one human study were available for review. The human study was an observational study of 2,205 pregnant women, 873 with asthma, of whom 9 took leukotriene modifiers, but the specific agent was not identified.¹¹ The conclusion is that minimal data are currently

Medication	Dosage Form	Adult Dose
Inhaled Corticosteroids (See Estimated Comparative Daily Dosages for Inhaled Corticosteroids.)		
Systemic Corticosteroids		(Applies to all three corticosteroids.)
Methylprednisolone	2, 4, 8, 16, 32 mg tablets	■ 7.5–60 mg daily in a single dose in a.m. or qod as needed for control
Prednisolone	5 mg tablets, 5 mg/5 cc, 15 mg/5 cc	■ Short-course “burst” to achieve control: 40–60 mg per day as single dose or 2 divided doses for 3–10 days
Prednisone	1, 2.5, 5, 10, 20, 50 mg tablets; 5 mg/cc, 5 mg/5 cc	
Long-Acting Inhaled Beta₂-Agonists (Should not be used for symptom relief or for exacerbations. Use with inhaled corticosteroids.)		
Salmeterol	MDI 21 mcg/puff	2 puffs q 12 hours
	DPI 50 mcg/blister	1 blister q 12 hours
Formoterol	DPI 12 mcg/single-use capsule	1 capsule q 12 hours
Combined Medication		
Fluticasone/Salmeterol	DPI 100, 250, or 500 mcg/50 mcg	1 inhalation bid; dose depends on severity of asthma
Cromolyn		
Cromolyn	MDI 1 mg/puff	2–4 puffs tid-qid
	Nebulizer 20 mg/ampule	1 ampule tid-qid
Leukotriene Receptor Antagonists		
Montelukast	10 mg tablet	10 mg qhs
Zafirlukast	10 or 20 mg tablet	40 mg daily (20 mg tablet bid)
Methylxanthines (Serum monitoring is important [serum concentration of 5–12 mcg/mL at steady state].)		
Theophylline	Liquids, sustained-release tablets, and capsules	Starting dose 10 mg/kg/day up to 300 mg max; usual max 800 mg/day

DPI, dry powder inhaler; MDI, metered-dose inhaler.

*Adapted from EPR—Update 2002.

Note:

- The most important determinant of appropriate dosing is the clinician’s judgment of the patient’s response to therapy.
- Some doses may be outside package labeling, especially in the high-dose range.

FIG 2. Usual dosages for long-term-control medications during pregnancy and lactation.*

Drug	Low Daily Dose	Medium Daily Dose	High Daily Dose
	Adult	Adult	Adult
Beclomethasone CFC 42 or 84 mcg/puff	168–504 mcg	504–840 mcg	>840 mcg
Beclomethasone HFA 40 or 80 mcg/puff	80–240 mcg	240–480 mcg	>480 mcg
Budesonide DPI 200 mcg/inhalation	200–600 mcg	600–1,200 mcg	>1,200 mcg
Flunisolide 250 mcg/puff	500–1,000 mcg	1,000–2,000 mcg	>2,000 mcg
Fluticasone MDI: 44, 110, or 220 mcg/puff	88–264 mcg	264–660 mcg	>660 mcg
DPI: 50, 100, or 250 mcg/inhalation	100–300 mcg	300–750 mcg	>750 mcg
Triamcinolone acetonide 100 mcg/puff	400–1,000 mcg	1,000–2,000 mcg	>2,000 mcg

DPI, dry powder inhaler; MDI, metered-dose inhaler.


*Adapted from EPR—Update 2002.

FIG 3. Estimated comparative daily dosages for inhaled corticosteroids.*

available on the use of leukotriene modifiers during pregnancy. Reassuring animal studies have been submitted to the Food and Drug Administration (FDA) for leukotriene receptor antagonists but not for the leukotriene lipooxygenase inhibitor.

RECOMMENDATIONS FOR MANAGING ASTHMA DURING PREGNANCY

The Working Group recommends the following principles and stepwise approach to pharmacologic therapy for



MDI, metered-dose inhaler; PEF, peak expiratory flow.

*Fetal activity is monitored by observing whether fetal kick counts decrease over time.


FIG 4. Management of asthma exacerbations during pregnancy and lactation: home treatment.

managing asthma during pregnancy. (See Figs 1–6.) The principles and approach are based on the Working Group's interpretation of the current scientific review of the evidence on the safety of asthma medications during pregnancy and consideration of previous NAEPP reports: the Asthma and Pregnancy Report 1993, the EPR-2 1997, and the EPR—Update 2002.

General principles

- The treatment goal for the pregnant asthma patient is to provide optimal therapy to maintain control of asthma for maternal health and quality of life as well as for normal fetal maturation. Asthma control is defined as:
 - Minimal or no chronic symptoms day or night

- Minimal or no exacerbations
- No limitations on activities
- Maintenance of (near) normal pulmonary function
- Minimal use of short-acting inhaled beta₂-agonist
- Minimal or no adverse effects from medications
- It is safer for pregnant women with asthma to be treated with asthma medications than for them to have asthma symptoms and exacerbations. Monitoring and making appropriate adjustments in therapy may be required to maintain lung function and, hence, blood oxygenation that ensures oxygen supply to the fetus. Inadequate control of asthma is a greater risk to the fetus than asthma medications are. Proper control of asthma should enable a woman with asthma to maintain a normal pregnancy with little or no risk to her or her fetus.



FEV₁, forced expiratory volume in 1 second; MDI, metered-dose inhaler; PCO₂, carbon dioxide partial pressure; PEF, peak expiratory flow.
Adapted from EPR-2 1997.

FIG 5. Management of asthma exacerbations during pregnancy and lactation: emergency department and hospital-based care.

Dosages			
Medications	Adult Doses	Child Dose	Comments
Short-Acting Inhaled Beta₂-Agonists			
Albuterol			
Nebulizer solution (5.0 mg/mL, 2.5 mg/3 mL, 1.25 mg/3 mL, 0.63 mg/3 mL)	2.5–5 mg every 20 minutes for 3 doses, then 2.5–10 mg every 1–4 hours as needed, or 10–15 mg/hour continuously	0.15 mg/kg (minimum dose 2.5 mg) every 20 minutes for 3 doses, then 0.15–0.3 mg/kg up to 10 mg every 1–4 hours as needed, or 0.5 mg/kg/hour by continuous nebulization	Only selective beta ₂ -agonists are recommended. For optimal delivery, dilute aerosols to minimum of 3 mL at gas flow of 6–8 L/min.
MDI (90 mcg/puff)	4–8 puffs every 20 minutes up to 4 hours, then every 1–4 hours as needed	4–8 puffs every 20 minutes for 3 doses, then every 1–4 hours inhalation maneuver; use spacer/holding chamber	As effective as nebulized therapy if patient is able to coordinate.
Bitolterol			
Nebulizer solution (2 mg/mL)	See albuterol dose	See albuterol dose; thought to be half as potent as albuterol on a mg basis	Has not been studied in severe asthma exacerbations. Do not mix with other drugs.
MDI (370 mcg/puff)	See albuterol dose	See albuterol dose	Has not been studied in severe asthma exacerbations.
Levalbuterol (R-albuterol)			
Nebulizer solution (0.63 mg/3 mL, 1.25 mg/3 mL)	1.25–2.5 mg every 20 minutes for 3 doses, then 1.25–5 mg every 1–4 hours as needed, or 5–7.5 mg/hour continuously	0.075 mg/kg (minimum dose 1.25 mg) every 20 minutes for 3 doses, then 0.075–0.15 mg/kg up to 5 mg every 1–4 hours as needed, or 0.25 mg/kg/hour by continuous nebulization	0.63 mg of levalbuterol is equivalent to 1.25 mg of racemic albuterol for both efficacy and side effects.
Pirbuterol			
MDI (200 mcg/puff)	See albuterol dose	See albuterol dose; thought to be half as potent as albuterol on a mg basis	Has not been studied in severe asthma exacerbations.
Systemic (Injected) Beta₂-Agonists			
Epinephrine 1:1000 (1 mg/mL)	0.3–0.5 mg every 20 minutes for 3 doses sq	0.01 mg/kg up to 0.3–0.5 mg every 20 minutes for 3 doses sq	No proven advantage of systemic therapy over aerosol.
Terbutaline (1 mg/mL)	0.25 mg every 20 minutes for 3 doses sq	0.01 mg/kg every 20 minutes for 3 doses, then every 2–6 hours as needed sq	No proven advantage of systemic therapy over aerosol.
Anticholinergics			
Ipratropium bromide			
Nebulizer solution (0.25 mg/mL)	0.5 mg every 30 minutes for 3 doses, then every 2–4 hours as needed	0.25 mg every 20 minutes for 3 doses, then every 2 to 4 hours	May mix in same nebulizer with albuterol. Should not be used as first-line therapy; should be added to beta ₂ -agonist therapy.
MDI (18 mcg/puff)	4–8 puffs as needed	4–8 puffs as needed	Dose delivered from MDI is low and has not been studied in asthma exacerbations.
Ipratropium with albuterol			
Nebulizer solution (Each 3 mL vial contains 0.5 mg ipratropium bromide and 2.5 mg albuterol)	3 mL every 30 minutes for 3 doses, then every 2–4 hours as needed	1.5 mL every 20 minutes for 3 doses, then every 2–4 hours	Contains EDTA to prevent discoloration. This additive does not induce bronchospasm.

FIG 6. Medications and dosages for asthma exacerbations during pregnancy and lactation.* (Continued on next page)

- The obstetrical care provider should be involved in asthma care, including monitoring of asthma status during prenatal visits. A team approach is helpful if more than one clinician is managing a pregnant woman with asthma.
- Asthma treatment is organized around four components of management:
 - **Assessment and monitoring of asthma, including objective measures of pulmonary function.** Because the course of asthma changes for about two-thirds of women during pregnancy,⁵³ monthly evaluations of asthma history and pulmonary function are recommended. Spirometry tests are recommended at the time of initial assessment.

Dosages			
Medications	Adult Doses	Child Dose	Comments
<i>Anticholinergics</i>			
MDI (Each puff contains 18 mcg ipratropium bromide and 90 mcg albuterol)	4–8 puffs as needed	4–8 puffs as needed	
<i>Systemic Corticosteroids</i> (Dosages and comments apply to all three corticosteroids)			
Prednisone	120–180 mg/day in 3 or 4 divided doses for 48 hours, then 60–80 mg/day until PEF reaches 70% of predicted or personal best	1 mg/kg every 6 hours for 48 hours, then 1–2 mg/kg/day (maximum = 60 mg/day) in 2 divided doses until PEF is 70% of predicted or personal best	For outpatient “burst” use 40–60 mg in single or 2 divided doses for adults (children: 1–2 mg/kg/day, maximum 60 mg/day) for 3–10 days.
Methylprednisolone			
Prednisolone			

*Adapted from EPR—Update 2002.

Note:

- The most important determinant of appropriate dosing is the clinician’s judgment of the patient’s response to therapy.
- No advantage has been found for higher dose corticosteroids in severe asthma exacerbations, nor is there any advantage for intravenous administration over oral therapy provided gastrointestinal transit time or absorption is not impaired. The usual regimen is to continue the frequent multiple daily dose until the patient achieves an FEV₁ or PEF of 50 percent of predicted or personal best and then lower the dose to twice daily. This usually occurs within 48 hours. Therapy following a hospitalization or emergency department visit may last from 3 to 10 days. If patients are then started on inhaled corticosteroids, studies indicate there is no need to taper the systemic corticosteroid dose. If the followup systemic corticosteroid therapy is to be given once daily, one study indicates that it may be more clinically effective to give the dose in the afternoon at 3 p.m., with no increase in adrenal suppression.⁵⁴

FIG 6. (Continued)

For routine monitoring at most subsequent followup outpatient visits, spirometry is preferable, but measurement of peak expiratory flow (PEF) with a peak flow meter is generally sufficient. Patients should be instructed to be attentive to fetal activity. Serial ultrasound examinations starting at 32 weeks gestation may be considered for patients who have suboptimally controlled asthma and for women with moderate to severe asthma. Ultrasound examinations are also helpful after recovery from a severe exacerbation.

- **Control of factors contributing to asthma severity.** Identifying and controlling or avoiding such factors as allergens and irritants, particularly tobacco smoke, that contribute to asthma severity can lead to improved maternal well-being with less need for medications. (See Fig 7.)
- **Patient education.** Asthma control is enhanced by ensuring access to education about asthma and about the skills necessary to manage it—such as self-monitoring, correct use of inhalers, and following a plan for managing asthma long term and for promptly handling signs of worsening asthma.
- **A stepwise approach to pharmacologic therapy.** In this approach to achieving and maintaining asthma control, the dose and number of medications and the frequency of administration are increased as necessary, based on the severity of the patient’s asthma, and are decreased when possible.

RECOMMENDATIONS FOR PHARMACOLOGIC TREATMENT OF ASTHMA DURING PREGNANCY

Stepwise approach for managing asthma. To develop recommendations for the stepwise approach to the pharmacologic treatment of asthma in pregnant women, the Working Group first considered the stepwise approach in the EPR—Update 2002, which was based on systematic review of the evidence from medication effectiveness studies in nonpregnant adults and children. The Working Group also considered EPR-2 1997 and the Asthma and Pregnancy Report 1993.

The effectiveness of medications is assumed to be the same in pregnant women as in nonpregnant women, although there are no studies that directly test this assumption. Based on their current systematic review of evidence from safety studies of asthma medications during pregnancy, the Working Group then tailored existing recommendations for stepwise therapy. Refer to Figs 1, 2, and 3 for a complete list of recommended therapies and medication dosages in the stepwise approach to managing asthma. The following information highlights the rationale for the preferred medications.

- **Step 1: Mild Intermittent Asthma.** Short-acting bronchodilators, particularly short-acting inhaled beta₂-agonists, are recommended as quick-relief medication for treating symptoms as needed in patients with intermittent asthma. Albuterol is the preferred short-acting inhaled beta₂-agonist because it has an excellent safety profile and the greatest amount of data related to safety during pregnancy of any currently available

Allergens:

Reduce or eliminate exposure to the allergen(s) the patient is sensitive to, including:

- Animal dander: Remove animal from house, or, at a minimum, keep animal out of patient's bedroom and seal or cover with a filter the air ducts that lead to the bedroom.
- House-dust mites:
 - Essential: Encase mattress in an allergen-impermeable cover; encase pillow in an allergen-impermeable cover or wash it weekly; wash sheets and blankets on the patient's bed in hot water weekly (water temperature of >130 °F is necessary for killing mites).
 - Desirable: Reduce indoor humidity to less than 50 percent; remove carpets from the bedroom; avoid sleeping or lying on upholstered furniture; remove carpets that are laid on concrete.
- Cockroaches: Use poison bait or traps to control. Do not leave food or garbage exposed.
- Pollens (from trees, grass, or weeds) and outdoor molds: To avoid exposure, adults should stay indoors—especially during the afternoon—with the windows closed during the season in which they have problems with outdoor allergens.
- Indoor mold: Fix all leaks and eliminate water sources associated with mold growth; clean moldy surfaces. Consider reducing indoor humidity to less than 50 percent.

Tobacco Smoke:

Advise patients and others in the home who smoke to stop smoking or to smoke outside the home. Discuss ways to reduce exposure to other sources of tobacco smoke, such as from daycare providers and the workplace.

Indoor/Outdoor Pollutants and Irritants:

Discuss ways to reduce exposures to the following:

- Wood-burning stoves or fireplaces
- Unvented stoves or heaters
- Other irritants (e.g., perfumes, cleaning agents, sprays)

*Adapted from EPR-2 1997.

FIG 7. Summary of control measures for environmental factors that can make asthma worse.*

inhaled beta₂-agonist. Women's experience with these drugs is extensive, and no evidence has been found either of fetal injury from the use of short-acting inhaled beta₂-agonists or of contraindication during lactation.

- **Step 2: Mild Persistent Asthma.** The preferred treatment for long-term-control medication in Step 2 is daily low-dose inhaled corticosteroid. This preference is based on the strong effectiveness data in non-pregnant women^{6,7} as well as effectiveness and safety data in pregnant women that show no increased risk of adverse perinatal outcomes. Budesonide is the preferred inhaled corticosteroid because more data are available on using budesonide in pregnant women than are available on other inhaled corticosteroids, and the data are reassuring. It is important to note that there are no data indicating that the other inhaled corticosteroid preparations are unsafe during pregnancy. Therefore, inhaled corticosteroids other than budesonide may be continued in patients who were well controlled by these agents prior to pregnancy, especially if it is thought that changing formulations may jeopardize asthma control.

Cromolyn, leukotriene receptor antagonists, and theophylline are listed as alternative but not preferred therapies. Cromolyn has an excellent safety profile, but it has limited effectiveness compared with inhaled corticosteroids. Leukotriene receptor antagonists have been

demonstrated to provide statistically significant but modest improvements in children and nonpregnant adults with asthma, although in studies comparing overall efficacy of the two drugs, most outcomes clearly favor inhaled corticosteroids. Published data are minimal on using leukotriene receptor antagonists during pregnancy; however, animal safety data submitted to the FDA are reassuring. Thus, leukotriene receptor antagonists are an alternative but not preferred treatment for pregnant women whose asthma was successfully controlled with this medication prior to their pregnancy. Theophylline has demonstrated clinical effectiveness in some studies and has been used for years in pregnant women with asthma. It also, however, has the potential for serious toxicity resulting from excessive dosing and/or select drug-drug interactions (e.g., with erythromycin). Using theophylline during pregnancy requires careful titration of the dose and regular monitoring to maintain the recommended serum theophylline concentration range of 5-12 mcg/mL.

- **Step 3: Moderate Persistent Asthma.** Two preferred treatment options are noted: either a combination of low-dose inhaled corticosteroid and a long-acting inhaled beta₂-agonist, or increasing the dose of inhaled corticosteroid to the medium dose range. No data from studies during pregnancy clearly delineate that one option is recommended over the other.

Limited data describe the effectiveness and/or safety of using combination therapy during pregnancy, but strong

evidence from randomized controlled trials in nonpregnant adults shows that adding long-acting inhaled beta₂-agonist to a low dose of inhaled corticosteroid provides greater asthma control than only increasing the dose of corticosteroid.⁷ The pharmacologic and toxicologic profiles of long-acting and short-acting inhaled beta₂-agonists are similar; there is justification for expecting long-acting inhaled beta₂-agonists to have a safety profile similar to that of albuterol, for which there are data related to safety during pregnancy. Two long-acting inhaled beta₂-agonists are available—salmeterol and formoterol. Limited observational data exist on their use during pregnancy; salmeterol might be chosen because it has been available longer in the United States.

Increasing the dose of inhaled corticosteroid to medium dose will benefit many patients, and, as noted previously, the data on using inhaled corticosteroids during pregnancy—including studies of large birth registries—are reassuring.

- **Step 4: Severe Persistent Asthma.** If additional medication is required after carefully assessing patient technique and adherence with using Step 3 medication, then the inhaled corticosteroid dose should be increased within the high-dose range, and the use of budesonide is preferred. If this is insufficient to manage asthma symptoms, then the addition of systemic corticosteroid is warranted; although the data are uncertain about some risks of oral corticosteroids during pregnancy, severe uncontrolled asthma poses a definite risk to the mother and fetus.

Management of acute exacerbations. Asthma exacerbations have the potential to lead to severe problems for the fetus. Therefore, asthma exacerbations during pregnancy should be managed aggressively. Refer to Fig 4 for home treatment of asthma exacerbation, Fig 5 for emergency department and hospital management, and Fig 6 for medications and dosages.

Pharmacologic management of allergic rhinitis. Rhinitis, sinusitis, and gastroesophageal reflux are conditions that are often associated with asthma, are frequently more troublesome during pregnancy, and may exacerbate coexisting asthma. If these conditions are present, appropriate treatment is an integral part of asthma management. These topics were outside the scope of the current evidence-based review, but relevant studies on the safety of rhinitis medications during pregnancy were reviewed in order to present the following recommendations.

- Intranasal corticosteroids are the most effective medications for the management of allergic rhinitis and have a low risk of systemic effect when used at recommended doses. Montelukast, a leukotriene receptor antagonist, can be used for the treatment of allergic rhinitis—but minimal data are available on the use of this medication during pregnancy.
- The current second-generation antihistamines of choice are loratadine or cetirizine.
- There may be a relationship between use of oral decongestants in early pregnancy and a rare birth defect,

gastroschisis; however, the absolute risk of gastroschisis in exposed fetuses is still extremely small. If nasal decongestion is indicated in early pregnancy, an external nasal dilator, short-term topical oxymetazoline, or intranasal corticosteroid can be considered before use of oral decongestants.

REFERENCES

1. Kwon HL, Belanger K, Bracken MB. Asthma prevalence among pregnant and childbearing-aged women in the United States: estimates from national health surveys. *Ann Epidemiol* 2003;13:317-24.
2. Demissie K, Breckenridge MB, Rhoads GG. Infant and maternal outcomes in the pregnancies of asthmatic women. *Am J Respir Crit Care Med* 1998;158:1091-5.
3. Källén B, Rydhstroem H, Åberg A. Asthma during pregnancy—a population based study. *Eur J Epidemiol* 2000;16:167-71.
4. Schatz M, Zeiger RS, Hoffman CP, Harden K, Forsythe A, Chilingar L, et al. Perinatal outcomes in the pregnancies of asthmatic women: a prospective controlled analysis. *Am J Respir Crit Care Med* 1995;151:1170-4.
5. Asthma and pregnancy report. NAEPP report of the Working Group on Asthma and Pregnancy: management of asthma during pregnancy. NIH publication no. 93-3279. Bethesda (MD): US Department of Health and Human Services; National Institutes of Health; National Heart, Lung, and Blood Institute, 1993. Available from URL: <http://www.nhlbi.nih.gov/health/prof/lung/asthma/astpreg.txt>. Accessed July 8, 2004.
6. EPR-2. NAEPP expert panel report 2: guidelines for the diagnosis and treatment of asthma. NIH publication no. 97-4051. Bethesda (MD): US Department of Health and Human Services; National Institutes of Health; National Heart, Lung, and Blood Institute, 1997. Available from URL: <http://www.nhlbi.nih.gov/guidelines/asthma/asthgdln.htm>. Accessed July 8, 2004.
7. EPR—Update 2002. NAEPP expert panel report: guidelines for the diagnosis and treatment of asthma—update on selected topics 2002. NIH publication no. 02-5074. Bethesda (MD): US Department of Health and Human Services; National Institutes of Health; National Heart, Lung, and Blood Institute, 2003. Available from URL: <http://www.nhlbi.nih.gov/guidelines/asthma/asthupdt.htm>. Accessed July 8, 2004.
8. EPR—Update 2004. NAEPP expert panel report: managing asthma during pregnancy: recommendations for pharmacologic treatment—update 2004. NIH publication no. 04-3279. Bethesda (MD): US Department of Health and Human Services; National Institutes of Health; National Heart, Lung, and Blood Institute, 2004.
9. Alexander DJ, Mather A, Dines GD. A snout-only inhalation exposure system for use in rabbit teratology studies. *Inhal Toxicol* 1997;9:477-90.
10. Baker ER, Flanagan MF. Fetal atrial flutter associated with maternal beta-sympathomimetic drug exposure. *Obstet Gynecol* 1997;89(5 Pt 2):861.
11. Bracken MB, Triche EW, Belanger K, Saftlas A, Beckett WS, Leaderer BP. Asthma symptoms, severity, and drug therapy: a prospective study of effects on 2205 pregnancies. *Obstet Gynecol* 2003;102:739-52.
12. Rayburn WF, Atkinson BD, Gilbert K, Turnbull GL. Short-term effects of inhaled albuterol on maternal and fetal circulations. *Am J Obstet Gynecol* 1994;171:770-3.
13. Schatz M, Zeiger RS, Harden K, Hoffman CC, Chilingar L, Petitti D. The safety of asthma and allergy medications during pregnancy. *J Allergy Clin Immunol* 1997;100:301-6.
14. Wilton LV, Pearce GL, Martin RM, Mackay FJ, Mann RD. The outcomes of pregnancy in women exposed to newly marketed drugs in general practice in England. *Br J Obstet Gynaecol* 1998;105:882-9.
15. Wilton LV, Shakir SA. A post-marketing surveillance study of formoterol (Foradil): its use in general practice in England. *Drug Saf* 2002;25:213-23.
16. Harris MW, Chapin RE, Lockhart AC, Jokinen MP. Assessment of a short-term reproductive and developmental toxicity screen. *Fundam Appl Toxicol* 1992;19:186-96.
17. Hart AD, Grimble RF. Effect of methylxanthines on lactational performance of rats. *Ann Nutr Metab* 1990;34:297-302.

18. Hart AD, Grimble RF. The effect of methylxanthines on milk volume and composition, and growth of rat pups. *Br J Nutr* 1990;64:339-50.
19. Lamb J, Gulati D, Chambers R, Shaver S, Sabharwal P. Reproductive toxicology. Theophylline. *Environ Health Perspect* 1997;105(Suppl):1355-6.
20. León D, Albasanz JL, Ruiz MA, Fernandez M, Martin M. Adenosine A1 receptor down-regulation in mothers and fetal brain after caffeine and theophylline treatments to pregnant rats. *J Neurochem* 2002;82:625-34.
21. Lindström P, Morrissey RE, George JD, Price CJ, Marr MC, Kimmel CA, et al. The developmental toxicity of orally administered theophylline in rats and mice. *Fundam Appl Toxicol* 1990;14:167-78.
22. Shibata M, Wachi M, Kawaguchi M, Kojima J, Onodera K. Teratogenic and fetal toxicity following intravenous theophylline administration in pregnant rabbits is related to maternal drug plasma levels. *Methods Find Exp Clin Pharmacol* 2000;22:101-7.
23. Agarwal HS, Nanavati RN, Bhagwat MS, Kabra NS, Udani RH. Transplacental aminophylline toxicity. *Indian Pediatr* 1998;35:467-70.
24. Park JM, Schmer V, Myers TL. Cardiovascular anomalies associated with prenatal exposure to theophylline. *South Med J* 1990;83:1487-8.
25. Dombrowski MP, Schatz M, Wise R, Thom EA, Landon M, Mabie W, et al. Randomized trial of inhaled beclomethasone dipropionate versus theophylline for moderate asthma during pregnancy. *Am J Obstet Gynecol* 2004;190:737-44.
26. Neff RK, Leviton A. Maternal theophylline consumption and the risk of stillbirth. *Chest* 1990;97:1266-7.
27. Stenius-Aarniala B, Riikonen S, Teramo K. Slow-release theophylline in pregnant asthmatics. *Chest* 1995;107:642-7.
28. Wendel PJ, Ramin SM, Barnett-Hamm C, Rowe TF, Cunningham FG. Asthma treatment in pregnancy: a randomized controlled study. *Am J Obstet Gynecol* 1996;175:150-4.
29. Rotschild A, Solimano A, Sekhon HS, Massoud EA, Thurlbeck WM. Effect of triamcinolone acetonide on the development of the pulmonary airways in the fetal rat. *Pediatr Pulmonol* 1997;23:76-86.
30. Sakamoto MK, Nakamura K, Handa J, Kihara T, Tanimura T. Studies of variant palatal rugae in normal and corticosteroid-treated mouse embryos. *Anat Rec* 1991;230:121-30.
31. Wise LD, Vetter CM, Anderson CA, Antonello JM, Clark RL. Reversible effects of triamcinolone and lack of effects with aspirin or L-656,224 on external genitalia of male Sprague-Dawley rats exposed in utero. *Teratology* 1991;44:507-20.
32. Alexander S, Dodds L, Armson BA. Perinatal outcomes in women with asthma during pregnancy. *Obstet Gynecol* 1998;92:435-40.
33. Dombrowski MP, Brown CL, Berry SM. Preliminary experience with triamcinolone acetonide during pregnancy. *J Matern Fetal Med* 1996;5:310-3.
34. Stenius-Aarniala BS, Hedman J, Teramo KA. Acute asthma during pregnancy. *Thorax* 1996;51:411-4.
35. Murphy VE, Zakar T, Smith R, Giles WB, Gibson PG, Clifton VL. Reduced 11beta-hydroxysteroid dehydrogenase type 2 activity is associated with decreased birth weight centile in pregnancies complicated by asthma. *J Clin Endocrinol Metab* 2002;87:1660-8.
36. Källén B, Rydhstroem H, Åberg A. Congenital malformations after the use of inhaled budesonide in early pregnancy. *Obstet Gynecol* 1999;93:392-5.
37. Norjavaara E, de Verdier MG. Normal pregnancy outcomes in a population-based study including 2,968 pregnant women exposed to budesonide. *J Allergy Clin Immunol* 2003;111:736-42.
38. Abbott BD, Dilberto JJ, Birnbaum LS. Mechanisms of TCDD-induction of cleft palate: insights from in vivo and in vitro approaches. *Chemosphere* 1992;25:75-8.
39. Abbott BD, Harris MW, Birnbaum LS. Comparisons of the effects of TCDD and hydrocortisone on growth factor expression provide insight into their interaction in the embryonic mouse palate. *Teratology* 1992;45:35-53.
40. Abbott BD, Perdew GH, Buckalew AR, Birnbaum LS. Interactive regulation of Ah and glucocorticoid receptors in the synergistic induction of cleft palate by 2,3,7,8-tetrachlorodibenzo-p-dioxin and hydrocortisone. *Toxicol Appl Pharmacol* 1994;128:138-50.
41. Abbott BD, Schmid JE, Brown JG, Wood CR, White RD, Buckalew AR, et al. RT-PCR quantification of AHR, ARNT, GR, and CYP1A1 mRNA in craniofacial tissues of embryonic mice exposed to 2,3,7,8-tetrachlorodibenzo-p-dioxin and hydrocortisone. *Toxicol Sci* 1999;47:76-85.
42. Dodic M, May CN, Wintour EM, Coghlan JP. An early prenatal exposure to excess glucocorticoid leads to hypertensive offspring in sheep. *Clin Sci (Lond)* 1998;94:149-55.
43. Jobe AH, Wada N, Berry LM, Ikegami M, Ervin MG. Single and repetitive maternal glucocorticoid exposures reduce fetal growth in sheep. *Am J Obstet Gynecol* 1998;178:880-5.
44. Tangalakakis K, Lumbers ER, Moritz KM, Towstoles MK, Wintour EM. Effect of cortisol on blood pressure and vascular reactivity in the ovine fetus. *Exp Physiol* 1992;77:709-17.
45. Uno H, Eisele S, Sakai A, Shelton S, Baker E, DeJesus O, et al. Neurotoxicity of glucocorticoids in the primate brain. *Horm Behav* 1994;28:336-48.
46. Watanabe C, Ishizuka Y, Nagao T. Palatal slit and cleft palate in rats treated with glucocorticoids—II. Comparative teratogenicity of prednisolone, triamcinolone acetonide and hydrocortisone. *Congenital Anomalies* 1995;35:133-40.
47. Park-Wyllie L, Mazzotta P, Pastuszak A, Moretti ME, Beique L, Hunnisett L, et al. Birth defects after maternal exposure to corticosteroids: prospective cohort study and meta-analysis of epidemiological studies. *Teratology* 2000;62:385-92.
48. Carmichael SL, Shaw GM. Maternal corticosteroid use and risk of selected congenital anomalies. *Am J Med Genet* 1999;86:242-4.
49. Czeizel AE, Rockenbauer M. Population-based case-control study of teratogenic potential of corticosteroids. *Teratology* 1997;56:335-40.
50. Robert E, Vollset SE, Botto L, Lancaster PAL, Merlob P, Mastroiacovo P, et al. Malformation surveillance and maternal drug exposure: the MADRE project. 1995. *Int J Risk Safe Med* 1994;6:75-118.
51. Rodríguez-Pinilla E, Martínez-Frias ML. Corticosteroids during pregnancy and oral clefts: a case-control study. *Teratology* 1998;58:2-5.
52. Perlow JH, Montgomery D, Morgan MA, Towers CV, Porto M. Severity of asthma and perinatal outcome. *Am J Obstet Gynecol* 1992;167(4 Pt 1):963-7.
53. Schatz M, Dombrowski MP, Wise R, Thom EA, Landon M, Mabie W, et al. Asthma morbidity during pregnancy can be predicted by severity classification. *J Allergy Clin Immunol* 2003;112:283-8.
54. Beam WR, Weiner DE, Martin RJ. Timing of prednisone and alterations of airways inflammation in nocturnal asthma. *Am Rev Respir Dis* 1992;146:1524-30.